<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39355719</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2690-442X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Skin health and disease</Title><ISOAbbreviation>Skin Health Dis</ISOAbbreviation></Journal><ArticleTitle>COVID-19 vaccination-linked granuloma annulare in two patients.</ArticleTitle><Pagination><StartPage>e412</StartPage><MedlinePgn>e412</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e412</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/ski2.412</ELocationID><Abstract><AbstractText>The COVID-19 pandemic brought not only a huge healthcare challenge to the world but also introduced many questions of how the human immune system reacts to counter viral invasion, including vaccination. Unlike most vaccinations that are not usually linked to any specific skin eruptions, COVID-19 vaccination has been linked to a variety of skin lesions. In this paper, we present two patients who developed granulomatous skin lesions post-COVID-19 vaccination, one patient has generalised granuloma annulare (GA) and the other patient develops localised GA. Both patients have good responses to treatment regimens containing systemic corticosteroids. We review the literature pertaining to COVID-19-linked skin diseases, particularly granulomatous diseases and discuss the possible pathomechanism of granulomatous eruptions in relation to COVID-19 vaccination.</AbstractText><CopyrightInformation>© 2024 The Author(s). Skin Health and Disease published by John Wiley &amp; Sons Ltd on behalf of British Association of Dermatologists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Dermatology UC-Davis School of Medicine Sacramento California USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamb</LastName><ForeName>Philina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Dermatology UC-Davis School of Medicine Sacramento California USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fung</LastName><ForeName>Maxwell A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Dermatology UC-Davis School of Medicine Sacramento California USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiuru</LastName><ForeName>Maija</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dermatology UC-Davis School of Medicine Sacramento California USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials><Identifier Source="ORCID">0009-0007-0640-980X</Identifier><AffiliationInfo><Affiliation>Department of Dermatology UC-Davis School of Medicine Sacramento California USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Skin Health Dis</MedlineTA><NlmUniqueID>9918227353706676</NlmUniqueID><ISSNLinking>2690-442X</ISSNLinking></MedlineJournalInfo><CoiStatement>None to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>4</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39355719</ArticleId><ArticleId IdType="pmc">PMC11442074</ArticleId><ArticleId IdType="doi">10.1002/ski2.412</ArticleId><ArticleId IdType="pii">SKI2412</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Marzano AV, Genovese G, Moltrasio C, Gaspari V, Vezzoli P, Maione V, et al. The clinical spectrum of COVID‐19–associated cutaneous manifestations: an Italian multicenter study of 200 adult patients. [Internet]. J Am Acad Dermatol. 2021;84(5):1356–1363. [cited 2022 Sep 12] Available from:. 10.1016/j.jaad.2021.01.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2021.01.023</ArticleId><ArticleId IdType="pmc">PMC7816892</ArticleId><ArticleId IdType="pubmed">33476725</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen VT, Chan LS. COVID‐19 infection: the virus and its origin, the variants, the immune defense, the multiorgan autoimmune reactions, and the targeted treatments. [Internet]. Adv Infect Dis. 2022;12(3):568–631. [cited 2023 Apr 8] Available from:. 10.4236/aid.2022.123042</Citation><ArticleIdList><ArticleId IdType="doi">10.4236/aid.2022.123042</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan SW, Tam YC, Oh CC. Skin manifestations of COVID‐19: a worldwide review. [Internet]. JAAD international. 2021;2:119–133. Available from:. 10.1016/j.jdin.2020.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdin.2020.12.003</ArticleId><ArticleId IdType="pmc">PMC7754879</ArticleId><ArticleId IdType="pubmed">33479703</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe T, Kawamura T, Jacob SE, Aquilino EA, Orenstein JM, Black JB, et al. Pityriasis rosea is associated with systemic active infection with both human herpesvirus‐7 and human herpesvirus‐6. [Internet]. J Invest Dermatol. 2002;119(4):793–797. [cited 2023 Apr 5] Available from:. 10.1046/j.1523-1747.2002.00200.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1523-1747.2002.00200.x</ArticleId><ArticleId IdType="pubmed">12406322</ArticleId></ArticleIdList></Reference><Reference><Citation>Gambichler T, Boms S, Susok L, Dickel H, Finis C, Abu Rached N, et al. Cutaneous findings following COVID‐19 vaccination: review of world literature and own experience. J Eur Acad Dermatol Venereol. 2021;36(2):172–180. 10.1111/jdv.17744</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.17744</ArticleId><ArticleId IdType="pmc">PMC8656409</ArticleId><ArticleId IdType="pubmed">34661927</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID‐19 vaccination: a registry‐based study of 414 cases. [Internet]. J Am Acad Dermatol. 2021;85(1):46–55. Available from:. 10.1016/j.jaad.2021.03.092</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2021.03.092</ArticleId><ArticleId IdType="pmc">PMC8024548</ArticleId><ArticleId IdType="pubmed">33838206</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TH, Gabros S, Friefeld S, Gupta A, Skopit S. Generalized granuloma annulare after COVID‐19 vaccination. JAAD Case Reports. 2022;25:18–21. 10.1016/j.jdcr.2022.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdcr.2022.05.003</ArticleId><ArticleId IdType="pmc">PMC9106646</ArticleId><ArticleId IdType="pubmed">35602910</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson L, Brockow K, Alm J, Cardona V, Caubet JC, Gomes E, et al. Vaccination and allergy: EAACI position paper, practical aspects. Pediatr Allergy Immunol. 2017;28(7):628–640. 10.1111/pai.12762</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pai.12762</ArticleId><ArticleId IdType="pubmed">28779496</ArticleId></ArticleIdList></Reference><Reference><Citation>Thong BY.‐H, Tan TC. Epidemiology and risk factors for drug allergy. [Internet]. Br J Clin Pharmacol. 2011;71(5):684–700. Available from:. 10.1111/j.1365-2125.2010.03774.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.2010.03774.x</ArticleId><ArticleId IdType="pmc">PMC3093074</ArticleId><ArticleId IdType="pubmed">21480948</ArticleId></ArticleIdList></Reference><Reference><Citation>Aquino MR, Bingemann TA, Nanda A, Maples KM. Delayed allergic skin reactions to vaccines. Allergy Asthma Proc. 2022;43(1):20–29. 10.2500/aap.2022.43.210105</Citation><ArticleIdList><ArticleId IdType="doi">10.2500/aap.2022.43.210105</ArticleId><ArticleId IdType="pubmed">34983706</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew CY, Mar A, Nikpour M, Saracino AM. Hydroxychloroquine in dermatology: new perspectives on an old drug. Australas J Dermatol. 2019;61(2). 10.1111/ajd.13168</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajd.13168</ArticleId><ArticleId IdType="pubmed">31612996</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi TP, Duvic M. Granuloma annulare: an updated review of epidemiology, pathogenesis, and treatment options. Am J Clin Dermatol. 2021;23(1):37–50. 10.1007/s40257-021-00636-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40257-021-00636-1</ArticleId><ArticleId IdType="pmc">PMC8423598</ArticleId><ArticleId IdType="pubmed">34495491</ArticleId></ArticleIdList></Reference><Reference><Citation>
Brodell RT. UpToDate [Internet]. Stratman E, Ofori AO, editors. www.uptodate.com. 2021.  [cited 2024 Jun 3] https://www.uptodate.com/contents/granuloma‐annulare‐management
</Citation></Reference><Reference><Citation>García‐Gil MF, Álvarez‐Salafranca M, Martínez García A, Ara‐Martín M. Generalized granuloma annulare after pneumococcal vaccination. An Bras Dermatol. 2021;96(1):59–63. 10.1016/j.abd.2020.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abd.2020.05.009</ArticleId><ArticleId IdType="pmc">PMC7838119</ArticleId><ArticleId IdType="pubmed">33267970</ArticleId></ArticleIdList></Reference><Reference><Citation>Monte‐Serrano J, García‐Gil MF, García‐García M, Casas‐Flecha I, Matovelle‐Ochoa C, Ara‐Martín M. Granuloma annulare triggered by SARS‐CoV‐2 infection: immunohistochemical staining. Dermatol Ther. 2021;34(3). 10.1111/dth.14897</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.14897</ArticleId><ArticleId IdType="pmc">PMC7995008</ArticleId><ArticleId IdType="pubmed">33599069</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeil MM, DeStefano F. Vaccine‐associated hypersensitivity. J Allergy Clin Immunol. 2018;141(2):463–472. 10.1016/j.jaci.2017.12.971</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2017.12.971</ArticleId><ArticleId IdType="pmc">PMC6602527</ArticleId><ArticleId IdType="pubmed">29413255</ArticleId></ArticleIdList></Reference><Reference><Citation>Piette EW, Rosenbach M. Granuloma annulare: pathogenesis, disease associations and triggers, and therapeutic options. [Internet]. J Am Acad Dermatol. 2016;75(3):467–479. Available from:. 10.1016/j.jaad.2015.03.055</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2015.03.055</ArticleId><ArticleId IdType="pubmed">27543210</ArticleId></ArticleIdList></Reference><Reference><Citation>Ada LS, Ruocco E, Gambardella A, O’Leary R, Gee SN. Granulomatous dysimmune reactions (sarcoidosis, granuloma annulare, and others) on differently injured skin areas. Clin Dermatol. 2014;32(5):646–653. 10.1016/j.clindermatol.2014.04.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clindermatol.2014.04.012</ArticleId><ArticleId IdType="pubmed">25160106</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>